Peptic ulcer refers to a category of gastrointestinal illnesses that includes gastritis, gastric ulcers, and Duodenal ulcers, as well as gastroesophageal reflux disease (GERD). PPI and H2 receptor antagonists, as well as acid neutralisation agents such as antacids and antibiotics against H. pylori infection, are among the medications used to treat peptic ulcers. However, for efficient treatment, these medicines are frequently taken in combination.
Factors driving the growth of the global peptic ulcer drugs market include growing prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D stimulation through government policies, increasing number of generic manufacturers of peptic ulcer drugs, changes in disease management, etc.
Furthermore, factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics are anticipated to promote the expansion of the global peptic ulcer drugs market size over the forecast period of 2019 to 2027.
However, peptic ulcer drug adverse effects, low pipeline productivity, and changes in drug pricing rules are projected to stymie the global peptic ulcer pharmaceuticals market's growth in the future years.
Increased use of non-steroidal anti-inflammatory medications (NSAIDs) like aspirin, as well as increased awareness of peptic ulcer treatment alternatives, are projected to propel the peptic ulcer pharmaceuticals market in the North American region.
Europe has the second-largest share of the peptic ulcer medications market, owing to the region's simple availability of effective peptic ulcer treatment alternatives.
Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in November 2019, RedHill Biopharma received the U.S. FDA approval for Talicia, a treatment for Helicobacter pylori (H. pylori) infection in adults, regardless of ulcer status.
No comments:
Post a Comment